Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Leukemia, Myeloid, Acute 92Myelodysplastic Syndromes 59Leukemia 30Leukemia, Myelomonocytic, Chronic 27Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Multiple Myeloma 8Recurrence 7Lymphoma 7Primary Myelofibrosis 6Myeloproliferative Disorders 5Hematologic Neoplasms 5Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myelomonocytic, Acute 4Leukemia, Erythroblastic, Acute 4Congenital Abnormalities 4Breast Neoplasms 4Anemia, Refractory, with Excess of Blasts 4Pancreatic Neoplasms 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Biphenotypic, Acute 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Renal Insufficiency 2

Interventions

Gemcitabine 13Cisplatin 8Capecitabine 8Fluorouracil 5pembrolizumab 4Oxaliplatin 4Sorafenib 3Leucovorin 3Erlotinib Hydrochloride 3trametinib 2regorafenib 2durvalumab 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Magnetic Resonance Spectroscopy 2Lapatinib 2trifluridine tipiracil drug combination 1tremelimumab 1spartalizumab 1seribantumab 1olutasidenib 1olaparib 1devimistat 1derazantinib 1dehydroftorafur 1cediranib 1cabozantinib 1Trifluridine 1Trastuzumab 1Therapeutics 1Sutures 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Bile Duct Neoplasms × Azacitidine × Clear all
NCT03684811 2023-11-18

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Novo Nordisk A/S

Phase 1/2 Completed
93 enrolled 24 charts
CNSGastrointestinal

Bile Duct Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡